Oral ondansetron reduces the proportion of referred children to a (paediatric) emergency department when added to oral rehydration therapy compared to oral rehydration therapy alone.
Bron
Verkorte titel
Aandoening
General practice, Paediatrics, Acute gastroenteritis, Child, Cost-effectiveness, Antiemetic
Ondersteuning
Onderzoeksproduct en/of interventie
Geen registraties gevonden.
Uitkomstmaten
Primaire uitkomstmaten
The proportion of referrals to a (paediatric) emergency department over a period of 5 days.
Achtergrond van het onderzoek
OBJECTIVE: To evaluate cost-effectiveness of ondansetron in children with acute gastro-enteritis (AGE )
and vomiting at a general practitioner cooperative out-of-hours service (OHS)
RESEARCH QUESTION: What is the cost-effectiveness of ondansetron and oral rehydration therapy
(ORT) compared to ORT alone?
HYPOTHESIS: With an effective one-intake-treatment that stops vomiting and consequently facilitates
ORT, referral rate will be reduced and consequently will reduce costs
STUDY DESIGN: Pragmatic Randomized Controlled Trial
STUDY POPULATION: Vomiting children aged 6 months to 6 years with AGE attending OHS
INTERVENTION: Oral ondansetron added to ORT
PRIMARY CLINICAL OUTCOME IN COST EFFECTIVENESS ANALYSIS: the number of referrals to a
paediatric emergency department prevented
SAMPLE SIZE We have to include 824 children in order to observe a significant reduction in referral rate from an expected 9% to 4.5%
ANTICIPATED HEALTHCARE EFFICIENCY GAIN: This intervention may prevent over 2000 hospital
admissions annually in the Netherlands
Doel van het onderzoek
Oral ondansetron reduces the proportion of referred children to a (paediatric) emergency department when added to oral rehydration therapy compared to oral rehydration therapy alone.
Onderzoeksopzet
Baseline (=T0), every hour after baseline for the first four hours (=T1 - T4) for the first day. Second day until the seventh (=T5-T11)
Onderzoeksproduct en/of interventie
Weight-based dose of oral ondansetron added to oral rehydration therapy.
Publiek
Y. Lisman-van Leeuwen
Groningen
The Netherlands
050-3637525
y.lisman-van.leeuwen@umcg.nl
Wetenschappelijk
Y. Lisman-van Leeuwen
Groningen
The Netherlands
050-3637525
y.lisman-van.leeuwen@umcg.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Aged 6 months to 6 years;
2. At least 24 hours with episodes of nonbilious, nonbloody vomiting;
3. At least one reported episode of vomiting within the four hours preceding presentation;
4. At least one episode of diarrhea during the period of illness;
5. Parental written informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Requiring direct referral to an emergency department according to GP;
2. Use of anti-emetics in the previous 6 hours;
3. Known renal failure or hypoalbuminemia (as this could affect the assessment of hydration status);
4. Known diabetes mellitus or inflammatory bowel disease (as this could increse the risk of a complicated course);
5. A history of abdominal surgery;
6. Known sensitivity to 5-HT3 receptor antagonists;
7. Known prolonged QT-interval;
8. Current use of QT-prolonging medication;
9. Previous enrolment in the study.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL4700 |
NTR-old | NTR4906 |
CCMO | NL50760 |